newsfilter
← Latest News
Business Wire·

Humanigen Announces Clinical Trial Collaboration to Evaluate Lenzilumab in Acute Graft Versus Host Disease

Humanigen is supporting the University of Birmingham to conduct a Phase 2/3, potentially registrational, clinical trial at IMPACT stem cell transplant centers across the United Kingdom The "Risk Adapted Therapy in Acute GvHD", or "RATinG", study